Clinical Development

12.2.2013 Clinical Development

Clinical Teams Should Re-Think Risk-Based Monitoring to Improve Their Bottom Line

By Jennifer Harrell, Research Analyst Often, news surrounding the clinical development process seems pretty grim.  R&D budgets are being slashed, promising new compounds fall short in late-stage trials, patients struggle to find and enroll...
 

11.26.2013 Clinical Development

Let’s Give Thanks for Specialized Clinical Trial Third-Party Vendors

By Nicole May, Research Analyst This Thanksgiving, let's all put down our forks and thank third-party vendors performing critical clinical trial tasks. Third-party clinical trial vendors provide Continue reading “Let’s Give Thanks for...
 

11.5.2013 Clinical Development

Expanding Schizophrenic Patients’ Treatment Options: A Look into Companies’ Clinical Pipelines

By Sarah Ray, Research Analyst Back in July, Biopharm Insight noted that a number of companies have drugs with new mechanisms of action (MoAs) that target patients’ negative and cognitive symptoms.  These compounds exist across various stages...
 

10.22.2013 Clinical Development

Positive Risk-Benefit Findings Prompt Gilead to Stop Leukemia Phase 3 Trials Early

By Victoria Cavicchi, Research Analyst In recent years, adaptive clinical trials have become popular among drug developers due to their flexibility and efficiency.  Adaptive trial designs allow clinical teams to modify current trials by unblinding...
 

10.10.2013 Clinical Development

When Reinventing the Wheel Is a Good Thing: Developing New Mechanisms of Action to Target Unmet Medical Needs

By Sarah Ray, Research Analyst With another patent cliff looming, many pharmaceutical and biotechnology companies are expanding their clinical pipelines — be it to incorporate new therapies, to concentrate on niche areas or to develop new mechanisms...
 

9.17.2013 Clinical Development

Early Clinical Trial Results Take a Bite Out of Malaria Vaccine Search

By Jennifer Harrell, Research Analyst Pesky mosquitoes have forced an early end to many swampy summer nights. But these parasites pose a much greater risk for the nearly 200 million people infected with malaria each year. In a small Phase 1 clinical...
 

9.11.2013 Clinical Development

Lose Weight Without Dieting? Belonarib Phase I Trial Results Show Promise

By Natalie DeMasi, Research Analyst The key to weight loss is to burn more calories than you consume. Most weight-loss drugs facilitate this process by curbing their patients’ appetites as they diet and exercise. But what if there were a drug...
 

8.20.2013 Clinical Development

Big Data’s Potentially Big Impact in Medical Affairs Decisions

By Victoria Cavicchi, Research Analyst Big data is quickly becoming a big deal in the pharmaceutical industry.  A number of clinical studies — including two from Winship Cancer Institute and NextBio — are leveraging big data to seek out distinct...
 

7.2.2013 Clinical Development

Verastem Attacks Cancer Stem Cells with Investigative Mesothelioma Treatment

By Jennifer Harrell, Research Analyst Biopharmaceutical company Verastem discussed its lead compound and the future of mesothelioma treatment at this month’s ASCO Annual Meeting presentations.  Development of the compound, VS-6063, represents...
 

6.18.2013 Biomarkers

Potential Product May Ring True for Hearing-Loss and Tinnitus Patients

By Sarah Ray, Research Analyst When some people hear a ringing in their ears, perhaps they think someone is talking about them.  Or, in an office environment, they may equate the noise to the steady hum of fluorescent lights.  For many, this scenario...